key: cord-0837344-mnejq01r authors: Moritz, Rose K.C.; Gutzmer, Ralf; Zimmer, Lisa; Meier, Friedegund; Ahmed, Misbah S.; Sell, Sabine; Schlaak, Max; Kapp, Florian; Sachse, Michael M.; Haferkamp, Sebastian; Welzel, Julia; Kähler, Katharina; Weichenthal, Michael title: SARS-CoV-2 infections in melanoma patients treated with PD-1-inhibitors- a survey of the German ADOREG melanoma registry. date: 2020-11-28 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.11.015 sha: 984881b6ba42ab4e36b3005c4122353aaacb0ec5 doc_id: 837344 cord_uid: mnejq01r nan Currently, a second dramatic upsurge of SARS-CoV-2 infection rates is observed across Europe and there is an urgent need to clarify the imminent risk for our melanoma patients under immune checkpoint inhibition (ICI). To this aim we reviewed the clinical course of disease for all patients included in the registry of the German working group of dermato-oncology (ADOreg, www.hautkrebsregister.de) database with confirmed SARS-CoV-2 infection. ICI treatment for melanoma might influence the clinical course of a SARS-CoV-2-infection in different ways: First, cancer patients in general have a compromised immune response and are at a higher risk for severe infections, as reported by Bitterman (2018) for influenza infections 1 . According to several reports from Wuhan (China), the risk for intensive care or mechanical ventilation was higher for cancer patients with COVID-19 compared to the general population, and even more marked when cancer treatment had been received within 14 days of disease onset 2,3 . Second, ICI therapy by itself does not seem to expose cancer patients to an elevated risk of severe infectionsIn the context of influenza infections, Bersanelli and colleagues (2020) even suggested beneficial effects to the immune response, making an argument that these patients might not be at a specific risk and even be protected from severe infections 4 . Flow cytometry studies showed that among others, PD-1 was increased in T-cells patients with COVID-19 who rapidly deteriorated 5 , suggesting a potential positive effect of a PD-1-blockade. Third, in several cases COVID-19 was associated with a cytokine release syndrome (CRS) due to a massive secretion of pro-inflammatory cytokines, and severe, acute systemic symptoms involving the IL-6-signalling pathway 6 . Similar cytokine release syndromes have been observed under checkpoint inhibition 7 . This might explain a tendency for more severe symptoms, a high rate of hospitalizations 8 and a worse outcome as reported by Robilotti et al. 9 However, it remains unclear if patients on checkpoint-inhibitor treatment are truly more susceptible for a cytokine release syndrome due to COVID-19. Lung cancer patients were highly represented in all analyzed patient groups and age distribution and comorbidities in these patients differ markedly from melanoma patients. Among 652 melanoma patients on active ICI in the registry, 13 patients from 10 skin cancer centers were identified between March and July 2020. Median age was 65 (26-88) years. The last treatment cycle was between 0 and 51 days (median: 17) prior to positive COVID-19 PCR-test result. Notably, in five cases the infection was presumably transmitted by medical or paramedical staff. Detailed patient data, treatment details, symptoms and outcome are summarized in table 1. Four patients had no symptoms associated with COVID-19 and seven had a mild to moderate clinical course. Most frequently flu-like symptoms, cough and dysgeusia were reported. Two patients were hospitalized due to severe symptoms. The first was a 63-year old with a history of hypothyroidism who was hospitalized for 10 days with diarrhea and fever. The latter, an 83-year old with multiple comorbidities receiving ipilimumab and nivolumab in a good general status (ECOG 0) developed fever, dyspnea, circulatory symptoms and diarrhea and received treatment in an intensive care unit due to ARDS for 31 days and with mechanical ventilation for 44 days. 50 days after onset of symptoms she was discharged without need of oxygenation, but currently remains in a reduced general condition (ECOG 3). Among seven patients with mild or moderate symptoms (age 26-71) one without relevant comorbidities had received ipilimumab and nivolumab and six PD1-monotherapy. Out of these six four had no comorbidities, one suffered from arterial hypertension and one had a history of severe cardiovascular disease with myocardial infarction, and a history of breast cancer. Out of four asymptomatic patients three had received combination ICI (age 62, 71, 87) and one PD1monotherapy (age 88). Each except one of them had risk factors for severe COVID-19 due to comorbidities (table 1) . In summary, we identified few COVID-19 cases among our patients with metastatic melanoma treated with ICI, and the observed course of the disease was mainly asymptomatic or mild without need for intensive care or mechanical ventilation. No exacerbation of immune-related adverse events was observed. One patient developed severe respiratory symptoms with ARDS and a cytokine release syndrome cannot be excluded in retrospect. Contrarily, three other patients who had also received ipilimumab and nivolumab with equally severe risk factors did not develop severe symptoms of COVID-19, underlining how COVID-19 intensity may vary markedly among individuals and factors other than age and comorbidities yet have to be identified. In the group of patients treated with PD-1-monotherapy only few patients were asymptomatic. Nevertheless, none had a very severe course of the disease, despite other risk factors such as age and comorbidities. Notably, we observed that patients <75 years and without relevant comorbidities frequently reported symptoms. This might either be explained by a less pronounced immune reaction in the comorbid and elderly or simply by a tendency to associate symptoms to pre-existing conditions rather than COVID-19. It is noteworthy that at least five patients were infected in medical or paramedical institutions. We therefore strongly advise to reconsider contacts to medical or paramedical staff in regions with a J o u r n a l P r e -p r o o f high rate of COVID-19-infections, particularly for patients with comorbidities, who are more susceptible to severe courses of the disease. Repeated COVID-19 testing of patients and medical staff involved must be encouraged. National and European guidelines for management of cancer during the COVID-19 pandemic offer medical and ethical guidance to reduce infection risks without jeopardizing effective and potentially life-saving treatments 10 . However, these recommendations need to be adapted to the local infection rate and the pressure on the health care system. The presented data support the authors' current strategy to avoid postponing, interrupting or pausing ICI treatment in melanoma patients due to the COVID-19 pandemic, since the beneficial effects on long term survival of approximately 50% of patients outweighs the potential risk of a severe COVID-19 infection. Influenza vaccines in immunosuppressed adults with cancer Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors CoViD-19 Immunopathology & Immunotherapy The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report Clinical characteristics and outcomes of Coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI). in American Assosiation for Cancer Determinants of COVID-19 disease severity in patients with cancer Cancer Patient Management During the COVID-19 Pandemic | ESMO ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work ☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests RG received research funding from Novartis research funding from Novartis and has served on advisory boards for Bristol-Myers Squibb Max Schlaak received honoraria and participated in advisory boards by Bristol-Myers Squibb